RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Bellerophon Therapeutics P/S 2024

Bellerophon Therapeutics P/S

0

Bellerophon Therapeutics Dividend yield

Ticker

BLPH

ISIN

US0787713009

WKN

A2PZZR

As of May 17, 2024, Bellerophon Therapeutics's P/S ratio stood at 0, a 0% change from the 11.44 P/S ratio recorded in the previous year.

The Bellerophon Therapeutics P/S history

Bellerophon Therapeutics Aktienanalyse

What does Bellerophon Therapeutics do?

Bellerophon Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of lung diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon's business model is based on the research and development of therapies for the treatment of severe respiratory diseases, particularly pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD). The company works closely with leading researchers and clinicians to develop innovative treatments that can improve the lives of patients with lung diseases. Bellerophon has several divisions aimed at expanding the portfolio of lung diseases. The first division is the development of INOpulse®, a therapy that improves lung function through inhaled nitric oxide (NO). This therapy specializes in the treatment of PH and has already been approved by the FDA in the United States, the European Commission, and other regulatory agencies worldwide. Another division of Bellerophon is the development of treatments using ultra-short-acting beta-agonists (uBAs), which are able to relax the respiratory muscles and improve breathing. This therapy specializes in the treatment of COPD and is based on a novel device designed to improve the effectiveness of uBA therapy. Bellerophon also has several programs in the pipeline for the development of therapies for the treatment of other lung diseases, including pulmonary fibrosis, lung cancer, and cystic fibrosis. These programs are still in the research phase but have the potential to bring forth new innovations in the future. Some of Bellerophon's products include INOpulse®, an inhaled nitric oxide treatment for PH, and the novel device that improves the effectiveness of uBA therapy for COPD. Additionally, the company is working on further product developments in the field of lung diseases. Overall, Bellerophon Therapeutics Inc has already made significant progress in the development of innovative therapies to improve lung function, particularly in the treatment of PH and COPD. With a strong pipeline of products and programs focused on exploring new therapies for the treatment of lung diseases, the company will continue to expand its position in the field of lung diseases and improve the lives of patients with severe respiratory diseases. Bellerophon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Bellerophon Therapeutics's P/S Ratio

Bellerophon Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Bellerophon Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Bellerophon Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Bellerophon Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Bellerophon Therapeutics Stock

What is the price-to-earnings ratio of Bellerophon Therapeutics?

The price-earnings ratio of Bellerophon Therapeutics is currently 0.

How has the price-earnings ratio of Bellerophon Therapeutics changed compared to last year?

The price-to-earnings ratio of Bellerophon Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Bellerophon Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Bellerophon Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Bellerophon Therapeutics affect the company?

An increase in the price-earnings ratio of Bellerophon Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Bellerophon Therapeutics affect the company?

A decrease in the price-earnings ratio of Bellerophon Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Bellerophon Therapeutics?

Some factors that influence the price-earnings ratio of Bellerophon Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Bellerophon Therapeutics pay?

Over the past 12 months, Bellerophon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bellerophon Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bellerophon Therapeutics?

The current dividend yield of Bellerophon Therapeutics is .

When does Bellerophon Therapeutics pay dividends?

Bellerophon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bellerophon Therapeutics?

Bellerophon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bellerophon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bellerophon Therapeutics located?

Bellerophon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bellerophon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bellerophon Therapeutics from 5/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/17/2024.

When did Bellerophon Therapeutics pay the last dividend?

The last dividend was paid out on 5/17/2024.

What was the dividend of Bellerophon Therapeutics in the year 2023?

In the year 2023, Bellerophon Therapeutics distributed 0 USD as dividends.

In which currency does Bellerophon Therapeutics pay out the dividend?

The dividends of Bellerophon Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bellerophon Therapeutics

Our stock analysis for Bellerophon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bellerophon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.